Subtype
High Grade Astrocytic Tumor
CI-CAN-00005503Explore in graph →
495 active trials2 approved drugs51 evidence items
- NCIt
- C102897
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005503Explore in graph →
Clinical trials
1,778 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05565118 | Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression | recruiting | Phase 1 | 10 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07003542 | A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas | recruiting | Phase 2 | 48 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05708352 | A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment | recruiting | Phase 2 | 170 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07748299 | NuvOx Expanded Access | available | — | — | NuvOx LLCINDUSTRY | 0 | Aug 5, 2026 | clinicaltrials |
| NCT03643549 | Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)(BORTEM-17) | recruiting | Phase 1 / Phase 2 | 63 | Haukeland University HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03868943 | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma(JAZZ) | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02152982 | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | active not recruiting | Phase 2 / Phase 3 | 447 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT06069726 | A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial(MOAB) | recruiting | Phase 2 | 80 | Duke UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07739017 | OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma(OPAL) | not yet recruiting | Phase 1 | 54 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03297125 | Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI | active not recruiting | — | 60 | Medical College of WisconsinOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03970447 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma(GBM AGILE) | recruiting | Phase 2 / Phase 3 | 2,250 | Global Coalition for Adaptive ResearchOTHER | 6 | Jul 30, 2026 | clinicaltrials |
| NCT04555577 | Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma | active not recruiting | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05781321 | Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | active not recruiting | Phase 2 | 170 | Mayo ClinicOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06991101 | Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma | recruiting | Phase 2 | 190 | Baptist Health South FloridaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07464925 | A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma | recruiting | Phase 1 | 30 | Tetragon Biosciences LtdINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07735819 | Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma | not yet recruiting | Phase 2 | 61 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05023551 | Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | active not recruiting | Early Phase 1 | 39 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Jul 29, 2026 | clinicaltrials |
| NCT05284643 | Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma | recruiting | N/A | 96 | University of MiamiOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT02208362 | Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma | active not recruiting | Phase 1 | 65 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03180502 | Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma | active not recruiting | Phase 2 | 120 | NRG OncologyOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07731555 | Characterization of the Blood-Brain Barrier in High-Grade Glioma Through Immunohistochemical, Transcriptional, Fluorescein and Radiological Analyses | recruiting | N/A | 100 | Patrick MorrisOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT01339052 | Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma | completed | Phase 2 | 65 | L. Nicolas Gonzalez Castro, MD, PhDOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05879250 | WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | recruiting | Phase 2 | 39 | Northwestern UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06973096 | CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy | active not recruiting | Phase 1 | 9 | University of PennsylvaniaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06672575 | A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06910306 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma | recruiting | N/A | 10 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04479696 | Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors | recruiting | N/A | 117 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04900792 | A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma(XACT-Fe-GBM-01) | active not recruiting | Phase 1 | 16 | Bryan AllenOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06177964 | Lerapolturev (PVSRIPO) in GBM | recruiting | Phase 2 | 92 | Darell BignerOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07715097 | Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 30 | Beijing Tricision Biotherapeutics IncINDUSTRY | 0 | Jul 20, 2026 | clinicaltrials |
| NCT02902757 | FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma | completed | N/A | 7 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03423628 | A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer | active not recruiting | Phase 1 | 159 | AstraZenecaINDUSTRY | 3 | Jul 17, 2026 | clinicaltrials |
| NCT07225621 | Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma | recruiting | Phase 2 | 103 | Alpheus Medical, Inc.INDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07712770 | Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma(PRECISE) | not yet recruiting | Early Phase 1 | 12 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03581292 | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | active not recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 5 | Jul 16, 2026 | clinicaltrials |
| NCT04623931 | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06850766 | The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma(TMZ-CHRONO) | recruiting | N/A | 50 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05660369 | CARv3-TEAM-E T Cells in Glioblastoma | recruiting | Phase 1 | 21 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03919071 | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | active not recruiting | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2026 | clinicaltrials |
| NCT04485949 | A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma | active not recruiting | Phase 2 | 99 | ImvaxINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03477513 | Personalized Radiation Therapy for GBM | completed | N/A | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07689721 | ctDNA-Guided Intraventricular Therapy for CNS Malignancies(GUIDE-CNS) | not yet recruiting | N/A | 77 | Alireza MansouriOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT06448286 | PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma | not yet recruiting | Phase 3 | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05835687 | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | active not recruiting | Phase 1 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05698199 | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) | completed | Phase 1 | 10 | Immunomic Therapeutics, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05720078 | UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3)(UNITED-3) | active not recruiting | N/A | 70 | Sunnybrook Health Sciences CentreOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06061809 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | active not recruiting | Phase 2 | 34 | ImmunityBio, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06388733 | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma | active not recruiting | Phase 3 | 450 | Ivy Brain Tumor CenterOTHER | 11 | Jul 1, 2026 | clinicaltrials |
| NCT06455189 | Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 6, 2026source: clinicaltrials